← Eichor
Condition: Braf Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Braf

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Phase 1/Phase 2 · 27 location(s) · Institut de Recherches Internationales Servier · NCT05786924Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients
Phase 2 · 1 location(s) · Anna Raciborska · NCT04943224The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line
Phase 2 · 1 location(s) · Zhejiang University · NCT07257653Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer
Phase 3 · 1 location(s) · National Cancer Institute, Naples · NCT06509126Primary and Acquired Resistance to Targeted Treatment in BRAF V600E-mutated Metastatic Colorectal Cancer
Phase N/A · 13 location(s) · Swiss Cancer Institute · NCT07617610A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer
NA · 45 location(s) · UNICANCER · NCT05639413XL092 and Cemiplimab in BRAF WT Thyroid Cancer
Phase 1 · 2 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT06902376Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma
Phase 2 · 1 location(s) · Eva Marie Erfurth, MD, PhD · NCT05525273Belvarafenib for CNS Efficacy in Patients With BRAF-Altered Solid Tumors
Phase 2 · 1 location(s) · Samsung Medical Center · NCT07688356MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
Phase 1/Phase 2 · 3 location(s) · Ann & Robert H Lurie Children's Hospital of Chicago · NCT06712875Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma
EARLY_Phase 1 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT04741997Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation
Phase 1 · 13 location(s) · Haisco Pharmaceutical Group Co., Ltd. · NCT06536400ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer
Phase 2 · 8 location(s) · National Cancer Institute, Naples · NCT06714357Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-
Phase N/A · 8 location(s) · Novartis Pharmaceuticals · NCT05868629Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Me
Phase 3 · 1 location(s) · Genmab · NCT07702032Dabrafenib and/or Trametinib Rollover Study
Phase 4 · 32 location(s) · Novartis Pharmaceuticals · NCT03340506Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC
Phase 2 · 3 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06542588cfDNA 5mC/5hmC Biomarkers to Predict Chemotherapy Response in Metastatic Colorectal Cancer
Phase N/A · 1 location(s) · City of Hope Medical Center · NCT07224815Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer
Phase N/A · 1 location(s) · Blokhin's Russian Cancer Research Center · NCT06449989Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma
Phase 2 · 1 location(s) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao · NCT06653517Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
Phase 1 · 4 location(s) · Rina Plattner · NCT04903119DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cance
Phase 2/Phase 3 · 16 location(s) · Cancer Research UK · NCT05768178A Study on Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)
Phase N/A · 1 location(s) · Fudan University · NCT06749015A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colo
Phase 2 · 1 location(s) · Blokhin's Russian Cancer Research Center · NCT06978400Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi
Phase N/A · 1 location(s) · John Kirkwood · NCT06599619Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer
Phase 2 · 1 location(s) · Fudan University · NCT06763029A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Phase 1 · 40 location(s) · Pfizer · NCT05355701Real-life Pharmacological Monitoring of Encorafenib-Binimetinib in the Treatment of Metastatic Melanoma
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06774989Combination Therapy for BRAF-V600E Metastatic CRCm
Phase 2 · 1 location(s) · Vall d'Hebron Institute of Oncology · NCT06411600A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours
Phase 1 · 6 location(s) · Ipsen · NCT07441707
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.